Table 2.

Data on antithrombotic treatment (according to “PP”) in subjects aged 45+ years (n=11,699) with a diagnosis of atrial fibrillation. Number of patients (percentage)

Treatment	Women	Men
	n=5,398	n=6,301
No treatment	2,201 (40.8)	2,478 (39.3)
ASA	1,414 (26.2)	1,463 (23.2)
Clopidogrel	29 (0.5)	23 (0.4)
ASA + clopidogrel	8 (0.2)	11 (0.2)
Warfarin	1,560 (28.9)	2,056 (32.6)
Warfarin + ASA	181 (3.4)	264 (4.2)
Warfarin + clopidogrel	4 (0.1)	6 (0.1)
Warfarin + ASA + clopidogrel	1 (0.0)	0 (0.0)

Prescription was classified as “per-protocol” (“PP”) if present the year before and the year of MI, or present among subjects without MI if present during at least three years, at least 50% of actual years after first recorded year of AF, or during both 2006 and 2007.